Key result
PKCbetaII inhibition with betaIIV5-3 reverses HF in rat models by restoring cardiac protein quality control.
Why the study?
Does selective PKCbetaII inhibition with betaIIV5-3 re-establish cardiac protein quality control and reverse heart failure in preclinical models?
Does selective PKCbetaII inhibition with betaIIV5-3 re-establish cardiac protein quality control and reverse heart failure in preclinical models?
Selective inhibition of PKCbetaII reverses heart failure in preclinical models by restoring cardiac protein quality control, suggesting a novel therapeutic target.
Answers are grounded in this paper and cite their sources.
May support PKCbetaII inhibition as a target in heart failure; hypothesis-generating in rat models and requires clinical translation.
Some genetic forms of human cardiomyopathy result from accumulation of damaged proteins. However, it is not known whether damaged proteins contribute to other forms of cardiomyopathies and heart failure (HF). We found that failing human hearts from two different etiologies displayed three fold increases in misfolded proteins, an ~50% decrease in proteasomal activity (the machinery that disposes of them) and an ~5 fold increase in levels and ~2.5 fold increased activity in cardiac protein kinase C betaII (PKCbetaII) relative to control hearts. Myocardial infarction‐induced and hypertension‐induced heart failure models in rats also exhibited a 50% reduction in cardiac proteasomal activity, an ~3 fold increase in damaged and misfolded proteins, as well as an ~3 fold increased PKCbetaII activity. PKCbetaII directly phosphorylated the proteasome and inhibited its activity, in vitro. Finally, we showed that sustained and selective PKCbetaII inhibition with betaIIV5‐3 (but not the selective inhibition of PKCbetaI, delta or epsilon) re‐established cardiac protein quality control and reversed HF in both models. Therefore, accumulation of abnormal proteins, disruption of protein quality control and increased activity of PKCbetaII appear to contribute to the pathophysiology of heart failure, suggesting that PKCbetaII inhibition may benefit patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2012) studied Heart failure. PKCbetaII inhibition with betaIIV5-3 vs. Control hearts / untreated models was evaluated on Cardiac protein quality control and heart failure reversal. Sustained and selective PKCbetaII inhibition with betaIIV5-3 re-established cardiac protein quality control and reversed heart failure in rat models of myocardial infarction and hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: